Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South …
…, E Mohr, C Laxmeshwar, C Hewison… - The Lancet Infectious …, 2018 - thelancet.com
Background Bedaquiline and delamanid have been approved for treatment of multidrug-resistant
(MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, …
(MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, …
[HTML][HTML] Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis
L Mbuagbaw, L Guglielmetti, C Hewison… - Emerging infectious …, 2019 - ncbi.nlm.nih.gov
Bedaquiline is recommended by the World Health Organization for the treatment of
multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data …
multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data …
Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort
C Hewison, U Khan, M Bastard… - Clinical Infectious …, 2022 - academic.oup.com
Background Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an
obstacle to treatment completion. Evaluate safety of longer MDR/RR-TB regimens …
obstacle to treatment completion. Evaluate safety of longer MDR/RR-TB regimens …
Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges
…, L D'Ambrosio, C Hewison… - European …, 2016 - Eur Respiratory Soc
The World Health Organization (WHO) estimated that 480 000 new multidrug-resistant (MDR)
tuberculosis (TB) cases occurred globally in 2014, with 190 000 deaths. Limited data are …
tuberculosis (TB) cases occurred globally in 2014, with 190 000 deaths. Limited data are …
[HTML][HTML] Novel FujiLAM assay to detect tuberculosis in HIV-positive ambulatory patients in four African countries: a diagnostic accuracy study
…, C Bossard, N Nkosi, Z Ndlovu, C Hewison… - The Lancet Global …, 2023 - thelancet.com
Background Development of rapid biomarker-based tests that can diagnose tuberculosis
using non-sputum samples is a priority for tuberculosis control. We aimed to compare the …
using non-sputum samples is a priority for tuberculosis control. We aimed to compare the …
Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid, and …
…, S Padayachee, MF Franke, C Hewison - Clinical Infectious …, 2022 - academic.oup.com
Background Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin
resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-…
resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-…
[HTML][HTML] The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
…, H Huerga, AJ Khan, CD Mitnick, C Hewison… - BMC infectious …, 2019 - Springer
Background At a time when programs were struggling to design effective regimens for the
treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of …
treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of …
Pregnancy and birth outcomes in patients with multidrug-resistant tuberculosis treated with regimens that include new and repurposed drugs
…, S Coutisson, ES Garavito, C Hewison… - Clinical Infectious …, 2024 - academic.oup.com
Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB)
treatment with bedaquiline and/or delamanid, 98% had favorable treatment …
treatment with bedaquiline and/or delamanid, 98% had favorable treatment …
Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis
…, W Docteur, G Gottlieb, C Hewison… - Clinical Infectious …, 2020 - academic.oup.com
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis,
but uptake has been slow globally. In the endTB (expand new drug markets for TB) …
but uptake has been slow globally. In the endTB (expand new drug markets for TB) …
[HTML][HTML] Bedaquiline and repurposed drugs for fluoroquinolone-resistant multidrug-resistant tuberculosis: how much better are they?
…, L Hovhannisyan, F Varaine, C Hewison - American journal of …, 2018 - atsjournals.org
Methods We performed a retrospective cohort analysis of patients who started MDR-TB
treatment in Armenia. Consecutive patients with confirmed fluoroquinolone-resistant MDR-TB …
treatment in Armenia. Consecutive patients with confirmed fluoroquinolone-resistant MDR-TB …